Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Revenue Per Share for the year ending December 31, 2023: USD 0.00

Biomea Fusion Inc Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Biomea Fusion Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Biomea Fusion Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Biomea Fusion Inc Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Biomea Fusion Inc Revenue Per Share for the year ending December 31, 2019 was USD 0.00.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends